Continuous or fixed-duration maintenance therapy in multiple myeloma (Registro nro. 22736)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03163nam a2200277 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260804154305.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Kumar, Shaji |
| Rol del Autor | Autor |
| 9 (RLIN) | 53732 |
| 245 ## - Titulo | |
| Titulo | Continuous or fixed-duration maintenance therapy in multiple myeloma |
| 300 ## - Páginas | |
| Paginación | páginas: 221-232 |
| 520 ## - Resumen | |
| Resumen | Background: Current treatment of newly diagnosed multiple myeloma involves lenalidomide maintenance therapy given until disease progression. The appropriate duration of maintenance therapy with lenalidomide has been unclear. Methods: In this phase 3 trial, we enrolled patients with standard-risk newly diagnosed multiple myeloma who were not undergoing up-front autologous stem-cell transplantation. After induction treatment with a proteasome inhibitor–lenalidomide combination, patients were randomly assigned to receive indefinite-duration (continuous) lenalidomide or fixed-duration lenalidomide (for 2 years). The primary end point was overall survival; the trial had 80% power to detect a 50% increase in median survival (from 5 years to 7.5 years), with a two-sided alpha level of 5%, 395 patients undergoing randomization, and 204 deaths occurring during 9 years of follow-up.<br/>Results: At the end of induction, 516 patients were randomly assigned to the indefinite-duration group (260 patients) or the fixed-duration group (256 patients). At a median follow-up of 86 months, overall survival did not differ significantly between the groups. With 80 deaths in each group, overall survival at 7 years was 68.6% in the indefinite-duration group and 69.0% in the fixed-duration group (difference, −0.4 percentage points; 95 confidence interval [CI], −9.0 to 8.3; P=0.93). Progression-free survival at 7 years was 36.1% in the indefinite-duration group and 29.7% in the fixed-duration group (difference, 6.4 percentage points; 95% CI, −2.6 to 15.4). The 5-year cumulative incidence of second primary cancers, excluding nonmelanoma skin cancer, was 11.2% with indefinite-duration lenalidomide and 8.3% with fixed-duration lenalidomide. More adverse events occurred with indefinite-duration lenalidomide; the incidence of nonhematologic events of grade 3 or higher was 48.2% with indefinite-duration therapy and 31.5% with fixed-duration therapy.<br/>Conclusions: In this phase 3 trial involving patients with standard-risk newly diagnosed multiple myeloma who were not undergoing up-front autologous stem-cell transplantation, indefinite-duration maintenance therapy after induction therapy did not result in significantly longer overall survival than fixed-duration maintenance therapy. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LEUCEMIA |
| 9 (RLIN) | 33873 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LIMFOMA |
| 9 (RLIN) | 53733 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 700 ## - Autor Personal | |
| Autor Personal | Jacobus, Susanna |
| 9 (RLIN) | 53735 |
| 700 ## - Autor Personal | |
| Autor Personal | Cohen, Adam |
| 9 (RLIN) | 53736 |
| 700 ## - Autor Personal | |
| Autor Personal | Weiss, Matthias |
| 9 (RLIN) | 53737 |
| 700 ## - Autor Personal | |
| Autor Personal | Callander, Natalie |
| 9 (RLIN) | 53738 |
| 700 ## - Autor Personal | |
| Autor Personal | Singh, Avina |
| 9 (RLIN) | 53739 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22636 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM003 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | SQB |
No hay ítems disponibles.